REDWOOD CITY, Calif., Sept. 30, 2015 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), focused on the development of novel products based on its proprietary technologies for precision metering of gas flow, today announced its participation in two upcoming investor conferences:
-
The Aegis 2015 Growth Conference on Thursday, October 8, 2015 at 3:00 PM PT at the Encore at Wynn Las Vegas in Las Vegas, NV.
-
Dawson James Securities 2015 Growth Stock Conference on Thursday, October 15, 2015 at 12:15 PM ET at the Wyndham Grand Hotel in Jupiter, FL.
About Capnia
Capnia, Inc. develops and commercializes novel products based on its proprietary technologies for precision metering of gas flow. Capnia's lead product CoSense is based on the Sensalyze™ Technology Platform. It is a portable, non-invasive device that rapidly and accurately measures carbon monoxide (CO) in exhaled breath. CoSense has 510(k) clearance for sale in the U.S. and has received CE Mark certification for sale in the European Union. CoSense is used for the monitoring of CO from internal sources (such as hemolysis, a dangerous condition in which red blood cells degrade rapidly), as well as external sources (such as CO poisoning and smoke inhalation). The initial target market is newborns with jaundice that are at risk for hemolysis, comprising approximately three million births in the U.S. and European Union. The Company's commercial, neonatology-focused product line also includes innovative pulmonary resuscitation solutions, including the NeoPIP™ Infant T-Piece Resuscitator and Universal T-Piece Circuit consumables. Capnia's proprietary therapeutic technology uses nasal, non-inhaled CO2 and is being evaluated to treat the symptoms of allergies, as well as the trigeminally-mediated pain conditions such as cluster headache, trigeminal neuralgia and migraine.
CONTACT: Michelle Carroll/Susie Kim
Argot Partners
212-600-1902
michelle@argotpartners.com
susan@argotpartners.com
Capnia, Inc.